

303: A new obesity startup, an acquisition gone wrong, & the future of Teledoc
Apr 18, 2024
Biotech veteran Clive Meanwell discusses his new obesity startup, Metsera, and competing with Wegovy and Zepbound. They also talk about Teledoc CEO's departure after 15 years, Teladoc's challenges post-COVID, and the future of obesity drug development.
Chapters
Transcript
Episode notes
1 2 3 4 5
Introduction
00:00 • 2min
Navigating Uncertainty: Teladoc's Post-COVID Challenges and Strategic Shifts
01:52 • 9min
Innovative Obesity Drug Development Strategies
10:47 • 8min
Exploring the Competitive Landscape in the Obesity Market
18:48 • 10min
Exploring Matera's Drug Development Strategy and Clinical Trial Approach
28:19 • 3min